AsianScientist (Dec. 17, 2013) – ScinoPharm has completed construction of its Changshu plant on a 16-acre site in China.
The facilities include an R&D process development center and a multipurpose API (active pharmaceutical ingredients) manufacturing plant.
A total of US$113 million was invested in this facility. The new plant will be dedicated to producing new international and generic drugs for the domestic demands of the Chinese market. The plant has already received drug production licenses from the Chinese FDA for 4 API products.
Dr. Jo Shen, president and CEO of ScinoPharm, stated that China would become the second largest pharmaceutical market in 2015. The completion of ScinoPharm’s Changshu plant significantly expands the company’s capacity to respond to increasing global market demands for generic and other cost effective products. The plant will also serve as the base for the company to develop its API business in China. ScinoPharm has already developed 9 of the top 20 oncological products used in China.
The Changshu plant is the first API production plant to be built in accordance with the latest GMP requirements announced by the China Food and Drug Administration (CFDA) and is expected to benefit from reduced competition resulting from many existing companies’ inability to comply with these much more stringent compliance requirements, according to the company.
——
Source: ScinoPharm.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
